ScinoPharm Taiwan Ltd (台灣神隆), which makes active pharmaceutical ingredients (APIs), said it expects adverse market conditions to continue to affect its business this year.
The company’s core business of exporting generic drugs has been hit by falling prices as a series of mergers and acquisitions (M&A) raised the bargaining power of US-based drug distributors through joint procurements, it said.
The company also said it expects continued headwinds from a stronger New Taiwan dollar, after sales last year declined 6 percent due to exchange-rate fluctuations.
ScinoPharm on Friday reported that net income last year fell 36 percent annually to NT$422 million (US$14.4 million), with sales dipping 13 percent to NT$3.52 billion.
Earnings per share were NT$0.53, it said.
The company’s clients have trimmed their orders for Paclitaxel, a chemotherapy for ovarian and breast cancer, amid an inventory correction, while shipments of other major generic drugs were delayed due to the replacement and integration of product lines and factories in the wake of M&As among clients, ScinoPharm said.
However, the company said that manufacturing contracts for newly approved antibiotics Baxdela and Vibativ helped offset some of the lost sales in generic drugs.
ScinoPharm said that its partnership with Baxter International Inc has begun to bear fruit as it expands into the generic oncology injectibles market.
The partnership with the US-based Baxter enables the companies to jointly develop formulations while sharing the risks and profits, ScinoPharm said.
Royalties from its anticoagulant Fondaparinux last year increased significantly from a year earlier, it added.
As for the operations of its Changshu plant in China’s Jiangsu Province, ScinoPharm said that the increase in the plant’s revenue contribution has not been as fast as expected due to the rapidly changing environmental safety and health-related laws in China.
The company will continue with its strategy of integrating niche APIs and venturing into formulation, chief executive officer Fred Chen (陳勇發) said in a statement.
In terms of product selection, the company aims to prioritize the distribution of vertically integrated injectables, including small molecule injections and peptide APIs, Chen said.
Regarding the contract research and manufacturing business, the company is seeking new projects in targeted therapy and orphan drugs that have shorter development cycles, he said.
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
Hon Hai Precision Industry Co (鴻海精密) yesterday said it would work with US chipmaker Intel Corp to jointly develop and deploy next-generation artificial intelligence (AI) infrastructure and intelligent computing platforms in a move to capture booming demand for AI computing systems. Hon Hai, also known as Foxconn Technology Group (富士康), said in a statement that the partnership would combine its global manufacturing scale, system integration expertise and AI data center deployment capabilities with Intel’s strengths in processor architecture, silicon technologies and software ecosystem. The companies said they plan to work on equipment used in AI data centers, including server racks powered by
Artificial intelligence (AI) agents would supplant smartphones as the center of people’s digital lives, fundamentally reshaping personal devices and driving a major computing upgrade cycle, Qualcomm Inc CEO Cristiano Amon said yesterday. In his keynote speech for this year’s Computex trade show in Taipei, Amon said that the rise of "agentic AI" — AI systems capable of reasoning, planning and carrying out tasks autonomously — would transform how people interact with technology across phones, PCs, vehicles and wearable devices. Describing the technology as the next major evolution in computing, Amon said that "2026 is the year of agents.” For decades, smartphones have sat
RSS